Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 10.39%.

  • Tarsus Pharmaceuticals' EBITDA Margin rose 372000.0% to 10.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.18%, marking a year-over-year increase of 811900.0%. This contributed to the annual value of 63.06% for FY2024, which is 7154200.0% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported EBITDA Margin of 10.39% as of Q3 2025, which was up 372000.0% from 19.86% recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year EBITDA Margin high stood at 31.04% for Q1 2021, and its period low was 4393.79% during Q4 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' EBITDA Margin had a median value of 81.84% in 2024 and averaged 778.46%.
  • Data for Tarsus Pharmaceuticals' EBITDA Margin shows a peak YoY increase of 42571600bps (in 2022) and a maximum YoY decrease of -37857700bps (in 2022) over the last 5 years.
  • Over the past 5 years, Tarsus Pharmaceuticals' EBITDA Margin (Quarter) stood at 4393.79% in 2021, then skyrocketed by 97bps to 136.63% in 2022, then plummeted by -135bps to 320.4% in 2023, then soared by 89bps to 35.06% in 2024, then soared by 70bps to 10.39% in 2025.
  • Its last three reported values are 10.39% in Q3 2025, 19.86% for Q2 2025, and 32.19% during Q1 2025.